The
lateral flow assay is one of the most convenient analytical
techniques for analyzing the immune response, but its applicability
to precise genetic analyses is limited by the false-positive signal
and tedious and inefficient hybridization steps. Here, we introduce
the CRISPR (clustered regularly interspaced short palindromic repeats)
/Cas system into the lateral flow assay, termed CRISPR/Cas9-mediated
lateral flow nucleic acid assay (CASLFA), to address such issues.
In this study, CASLFA is utilized to identify Listeria monocytogenes, genetically modified organisms (GMOs), and African swine fever
virus (ASFV) at a detection limit of hundreds of copies of genome
samples with high specificity within 1 h. We further evaluated the
performance of CASLFA in a nonlaboratory environment and successfully
confirmed 27 ASFV-infected samples from 110 suspected swine serum
samples, with an accuracy of 100% when compared to real-time PCR (RT-PCR)
assay. CASLFA satisfies some of the characteristics of a next-generation
molecular diagnostics tool due to its rapidity and accuracy, allowing
for point-of-care use without the need for technical expertise and
complex ancillary equipment. This method has great potential for gene
analysis in resource-poor or nonlaboratory environments.